Coherus Queries Higher Dose Aflibercept Amid Biosimilar Eylea Deal
Potential For More Ophthalmology Products With ‘Additional Bandwidth’
Executive Summary
Coherus BioSciences is feeling bullish about its potential in the biosimilar ophthalmology space after agreeing to bring on board a biosimilar Eylea (aflibercept) candidate, with an eye on launching potentially in 2025.
You may also be interested in...
Roche Clinical Lead Labels Lucentis Biosimilars ‘Pandora’s Box’
Eight months after biosimilar competition to Roche’s Lucentis (ranibizumab) emerged in the US, ophthalmologists and doctors remain confused about how to incorporate them into their practice, a clinical trial lead representing the Swiss originator has proffered.
Eylea Race Continues To Heat Up With Formycon Unveiling Early Positive Data
Weeks after Coherus BioSciences put pen to paper on a deal to bring in Formycon’s FYB203 proposed biosimilar to Eylea (aflibercept), the candidate has shown positive efficacy and safety data, according to preliminary Phase III trial results.
Bullish Bayer Highlights Four Future Blockbusters
The German group has shone a light at the J.P. Morgan Healthcare Conference on its new launched drugs Nubeqa and Kerendia, plus its late-stage candidates asundexian and elinzanetant, as it prepares for life after patent expiries on Xarelto and Eylea.